The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Human Disease-Drug Network Based on Genomic Expression Profiles
Open accessAbstract
BACKGROUND: Drug repositioning offers the possibility of faster development times and reduced risks in drug discovery. With the rapid development of high-throughput technologies and ever-increasing accumulation of whole genome-level datasets, an increasing number of diseases and drugs can be comprehensively characterized by the changes they induce in gene expression, protein, metabolites and phenotypes. METHODOLOGY/PRINCIPAL FINDINGS: We performed a systematic, large-scale analysis of genomic expression profiles of human diseases and drugs to create a disease-drug network. A network of 170,027 significant interactions was extracted from the approximately 24.5 million comparisons between approximately 7,000 publicly available transcriptomic profiles. The network includes 645 disease-disease, 5,008 disease-drug, and 164,374 drug-drug relationships. At least 60% of the disease-disease pairs were in the same disease area as determined by the Medical Subject Headings (MeSH) disease classification tree. The remaining can drive a molecular level nosology by discovering relationships between seemingly unrelated diseases, such as a connection between bipolar disorder and hereditary spastic paraplegia, and a connection between actinic keratosis and cancer. Among the 5,008 disease-drug links, connections with negative scores suggest new indications for existing drugs, such as the use of some antimalaria drugs for Crohn's disease, and a variety of existing drugs for Huntington's disease; while the positive scoring connections can aid in drug side effect identification, such as tamoxifen's undesired carcinogenic property. From the approximately 37K drug-drug relationships, we discover relationships that aid in target and pathway deconvolution, such as 1) KCNMA1 as a potential molecular target of lobeline, and 2) both apoptotic DNA fragmentation and G2/M DNA damage checkpoint regulation as potential pathway targets of daunorubicin. CONCLUSIONS/SIGNIFICANCE: We have automatically generated thousands of disease and drug expression profiles using GEO datasets, and constructed a large scale disease-drug network for effective and efficient drug repositioning as well as drug target/pathway identification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence of Scaling in Random Networks
Barabási, A.-L., & Albert, R. (1999) · Science · doi:10.1126/science.286.5439.509 · Cited by 36,135
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · cited 2×
“R code was used to calculate the correlation significance P values, and Storey’s FDR method was used calculate the false discovery rate q values via the R package ‘‘QVALUE’’ [63].”
MethodNetwork biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Functional Discovery via a Compendium of Expression Profiles
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00015-5 · Cited by 2,533
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
A Protein Interaction Map of Drosophila melanogaster
Giot, L., Bader, J. S., Brouwer, C., Chaudhuri, A., Kuang, B., Li, Y., Hao, Y. L., Ooi, C. E., Godwin, B., Vitols, E., et al. (2003) · Science · doi:10.1126/science.1090289 · Cited by 1,863
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Baldi, P., & Long, A. D. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.6.509 · Cited by 1,618
NCBI GEO: mining tens of millions of expression profiles--database and tools update
Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P., Rudnev, D., Evangelista, C., Kim, I. F., Soboleva, A., Tomashevsky, M., & Edgar, R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl887 · Cited by 1,522
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Hopkins, A. L. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1110 · Cited by 1,242
Prediction of drug–target interaction networks from the integration of chemical and genomic spaces
Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W., & Kanehisa, M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn162 · Cited by 1,147
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · cited 1×
“This enables an automated, somewhat comprehensive monitoring of the changes of various molecular components associated with different disease states and drug treatments, therefore enables the characterization of disease and drug effects, and an elucidation of their relationships at a molecular systems level [6–12].”
BackgroundA human phenome-interactome network of protein complexes implicated in genetic disorders
Lage, K., Karlberg, E. O., Størling, Z. M., Ólason, P. Í., Pedersen, A. G., Rigina, O., Hinsby, A. M., Tümer, Z., Pociot, F., Tommerup, N., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1295 · Cited by 889
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Loscalzo, J., Kohane, I., & Barabasi, A. (2007) · Molecular Systems Biology · doi:10.1038/msb4100163 · Cited by 603
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sarkar, S., Perlstein, E. O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R. L., Webster, J. A., Lewis, T. A., O'Kane, C. J., Schreiber, S. L., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio883 · Cited by 596
Cancer risk after a hospital discharge diagnosis of endometriosis
Brinton, L. A., Gridley, G., Persson, I., Baron, J., & Bergqvist, A. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70550-7 · Cited by 547
A calculated response: control of inflammation by the innate immune system
Barton, G. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34431 · Cited by 532 · cited 1×
“For examples, many cancers involve common tumor activators (such as Ras and Myc) or tumor suppressors (such as p53 and PTEN) [36], while most inflammatory diseases are associated with the changes of cytokines and chemokines [37].”
BackgroundThe implications of human metabolic network topology for disease comorbidity
Lee, D.-S., Park, J., Kay, K. A., Christakis, N. A., Oltvai, Z. N., & Barabási, A.-L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802208105 · Cited by 495
Mechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
Fink, J. K. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0011-1 · Cited by 321
Probing genetic overlap among complex human phenotypes
Rzhetsky, A., Wajngurt, D., Park, N., & Zheng, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704820104 · Cited by 298
Ganter, B., Tugendreich, S., Pearson, C. I., Ayanoglu, E., Baumhueter, S., Bostian, K. A., Brady, L., Browne, L. J., Calvin, J. T., Day, G.-J., et al. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.03.022 · Cited by 285
Vanhaecke, T., Papeleu, P., Elaut, G., & Rogiers, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365099 · Cited by 255
Endometriosis and ovarian cancer: Thoughts on shared pathophysiology
Ness, R. B. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.408 · Cited by 229
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.43 · Cited by 213 · cited 1×
“These hypotheses are aligned with some published studies [44–49].”
ResultChen, E. S., Hripcsak, G., Xu, H., Markatou, M., & Friedman, C. (2008) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m2401 · Cited by 210
Creation and implications of a phenome-genome network
Butte, A. J., & Kohane, I. S. (2006) · Nature Biotechnology · doi:10.1038/nbt1150 · Cited by 205
Antibiotics and Risk of Subsequent First-time Acute Myocardial Infarction
Meier, C. R. (1999) · JAMA · doi:10.1001/jama.281.5.427 · Cited by 195
Altered platelet protein kinase C activity in bipolar affective disorder, manic episode
Friedman, E., Hoau-Yan-Wang, Levinson, D., Connell, T. A., & Singh, H. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90006-y · Cited by 194
Signaling pathways activated by daunorubicin
Laurent, G., & Jaffrézou, J.-P. (2001) · Blood · doi:10.1182/blood.v98.4.913 · Cited by 187
Roewert-Huber, J., Stockfleth, E., & Kerl, H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08267.x · Cited by 173
Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila
Agrawal, N., Pallos, J., Slepko, N., Apostol, B. L., Bodai, L., Chang, L.-W., Chiang, A.-S., Thompson, L. M., & Marsh, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500055102 · Cited by 162
Estradiol Augments while Tamoxifen Inhibits Rat Mast Cell Secretion
Vliagoftis, H., Dimitriadou, V., Boucher, W., Rozniecki, J. J., Correia, I., Raam, S., & Theoharides, T. C. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000236217 · Cited by 158 · cited 1×
“For example, tamoxifen inhibits mast cell secretion in a rat study, probably via PKC [47].”
BackgroundA Preliminary Investigation of a Protein Kinase C Inhibitor in the Treatment of Acute Mania
Bebchuk, J. M., Arfken, C. L., Manji, S., Murphy, J., Hasanat, K., & Manji, H. K. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.95 · Cited by 152
Endometriosis: Pathogenesis, diagnosis, therapy and association with cancer (Review)
Baldi, A., Campioni, M., & Signorile, P. G. (2008) · Oncology Reports · doi:10.3892/or.19.4.843 · Cited by 145
Understanding the genotoxicity of tamoxifen?
Phillips, D. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.839 · Cited by 133
Kulkarni, J., Garland, K. A., Scaffidi, A., Headey, B., Anderson, R., de Castella, A. R., Fitzgerald, P. B., & Davis, S. R. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.11.001 · Cited by 118
A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity
Fielden, M. R., Eynon, B. P., Natsoulis, G., Jarnagin, K., Banas, D. A., & Kolaja, K. L. (2005) · Toxicologic Pathology · doi:10.1080/01926230500321213 · Cited by 106
Rossi, R., Mori, M., & Lotti, T. (2007) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2007.03166.x · Cited by 94
Hahn, C.-G., Umapathy, Wang, H.-Y., Koneru, R., Levinson, D. F., & Friedman, E. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.10.007 · Cited by 93
Vazza, G., Zortea, M., Boaretto, F., Micaglio, G. F., Sartori, V., & Mostacciuolo, M. L. (2000) · The American Journal of Human Genetics · doi:10.1086/303017 · Cited by 76
Crohn’s Disease: A Review of Current Treatment with a Focus on Biologics
Panés, J., Gomollón, F., Taxonera, C., Hinojosa, J., Clofent, J., & Nos, P. (2007) · Drugs · doi:10.2165/00003495-200767170-00005 · Cited by 70
Lobelane decreases methamphetamine self-administration in rats
Neugebauer, N. M., Harrod, S. B., Stairs, D. J., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.003 · Cited by 67
Bell, T. J., Miyashiro, K., Sul, J., McCullough, R., Buckley, P. T., Jochems, J., Meaney, D. F., Haydon, P. G., Cantor, C. R., Parsons, T. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711796105 · Cited by 66
Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal: Current Status
Buchhalter, A. R., Fant, R. V., & Henningfield, J. E. (2008) · Drugs · doi:10.2165/00003495-200868080-00005 · Cited by 59
Järvinen, T. A. H., & Liu, E. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778742497 · Cited by 57
Butte, A. J. (2008) · Science · doi:10.1126/science.1158343 · Cited by 49
The mTOR Pathway as a Potential Target for the Development of Therapies Against Neurological Disease
Zemke, D., Azhar, S., & Majid, A. (2007) · Drug News & Perspectives · doi:10.1358/dnp.2007.20.8.1157618 · Cited by 43
Endometrial Cancer and Tamoxifen
Burke, C. (2005) · Clinical journal of oncology nursing · doi:10.1188/05.cjon.247-249 · Cited by 18
Tanner, S. W., & Agarwal, P. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-348 · Cited by 15
Self-citation
Cited by
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Network-based in silico drug efficacy screening
Guney, E., Menche, J., Vidal, M., & Barábasi, A.-L. (2016) · Nature Communications · doi:10.1038/ncomms10331 · Cited by 625
“Gene expression profile consistency based approaches aim to overcome these limitations by investigating correlations between the expression signatures of drug perturbations and the expression profiles in diseases 22,23 .”
Background
Metadata
- Authors
- Hu, G., & Agarwal, P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-08-06
- Volume
- 4
- Issue
- 8
- Pages
- e6536
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2061016350
- Cited by
- 310
- References
- 57
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.